Janux Therapeutics, Inc. Contracts & Agreements
30 Contracts & Agreements
- Business Finance (10 contracts)
- Business Operations (2)
- Human Resources (15)
- Intellectual Property (1)
- Real Estate (1)
- Uncategorized (1)
- Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on August 7, 2024)
- Amended and Restated Janux Therapeutics, Inc. 2021 Equity Incentive Plan, Forms of Option Grant Notice, Option Agreement and Notice of Exercise thereunder, and Forms of RSU Award... (Filed With SEC on August 7, 2024)
- Janux Therapeutics, Inc. Incentive Compensation Recoupment Policy (Filed With SEC on March 8, 2024)
- Employment Agreement, by and between the Registrant and Tommy DiRaimondo, Ph.D., dated January 1, 2021 (Filed With SEC on March 8, 2024)
- Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on March 8, 2024)
- Form of Pre-Funded Warrant (Filed With SEC on February 29, 2024)
- Underwriting Agreement, dated February 28, 2024, by and among Janux Therapeutics, Inc. and BofA Securities, Inc., Cowen and Company, LLC, Cantor Fitzgerald & Co. and William Blair... (Filed With SEC on February 29, 2024)
- Form of Pre-Funded Warrant (Filed With SEC on July 18, 2023)
- Underwriting Agreement, between the Company and BofA Securities, Inc., dated as of July 17, 2023 (Filed With SEC on July 18, 2023)
- Employment Agreement, by and between the registrant and Byron Robinson, Ph.D., dated January 20, 2022 (Filed With SEC on March 18, 2022)
- Employment Agreement, by and between the registrant and Shahram Salek-Ardakani, Ph.D., dated May 11, 2021 (Filed With SEC on March 18, 2022)
- Description of Registrants Common Stock (Filed With SEC on March 18, 2022)
- Lease, by and between the Registrant and UTC Properties LLC, dated August 25, 2021 (Filed With SEC on November 9, 2021)
- Non-Employee Director Compensation Policy (Filed With SEC on June 7, 2021)
- Employment Agreement, by and between the registrant and Wayne Godfrey, M.D., dated May 4, 2021 (Filed With SEC on June 7, 2021)
- Janux Therapeutics, Inc. 2021 Employee Stock Purchase Plan (Filed With SEC on June 7, 2021)
- Janux Therapeutics, Inc. 2021 Equity Incentive Plan, and Forms of Option Grant Notice, Option Agreement and Notice of Exercise thereunder (Filed With SEC on June 7, 2021)
- Amended and Restated Investors Rights Agreement, by and between the registrant and certain of its stockholders, dated April 15, 2021, as amended (Filed With SEC on June 7, 2021)
- Form of Common Stock Certificate of the registrant (Filed With SEC on June 7, 2021)
- Form of Underwriting Agreement (Filed With SEC on June 7, 2021)
- Amended and Restated Investors Rights Agreement, by and between the registrant and certain of its stockholders, dated April 15, 2021 (Filed With SEC on May 19, 2021)
- Janux Therapeutics, Inc. 2021 Change in Control and Severance Benefit Plan (Filed With SEC on May 19, 2021)
- Consulting Agreement by and between the registrant and Sheila Gujrathi, M.D., dated March 10, 2021 (Filed With SEC on May 19, 2021)
- Cell Line License Agreement by and between the registrant and WuXi Biologics (Hong Kong) Limited, dated April 19, 2021 (Filed With SEC on May 19, 2021)
- Support Services Agreement by and between the registrant and COI Pharmaceuticals, Inc., dated January 1, 2021 (Filed With SEC on May 19, 2021)
- Research Collaboration and Exclusive License Agreement by and between the registrant and Merck Sharp & Dohme Corp., dated December 17, 2020 (Filed With SEC on May 19, 2021)
- Employment Agreement by and between the registrant and Andy Meyer, dated February 17, 2021 (Filed With SEC on May 19, 2021)
- Employment Agreement, by and between the registrant and David Campbell, Ph.D., dated January 1, 2021 (Filed With SEC on May 19, 2021)
- Janux Therapeutics, Inc. 2017 Equity Incentive Plan, as amended, and Forms of Option Agreement, Notice of Exercise and Early Exercise Stock Purchase Agreement thereunder (Filed With SEC on May 19, 2021)
- Form of Indemnity Agreement, by and between the registrant and its directors and officers (Filed With SEC on May 19, 2021)